Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Durvalumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Durvalumab + BA3011 (Arm Closed) | EXPERIMENTAL | - |
| Durvalumab + BA3021 (Arm Closed) | EXPERIMENTAL | - |
| ENB-003 + Toripalimab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Durvalumab | DRUG | 1500mg IV, 60 min day 1 every 4 weeks |
| BA3011 | DRUG | IV |
| BA3021 | DRUG | IV |
| ENB003 | DRUG | IV |
| Toripalimab | DRUG | IV |
Inclusion Criteria: * This study will enroll women with platinum resistant high grade serous ovarian cancer. * This study is open to minorities as appropriate but is not designed to measure differences in intervention effects. * All patients must be registered for screening prior to study enrollmen...
Top 20 of 59 competitors
Durvalumab is being studied for the treatment of platinum resistant high grade serous ovarian cancer. It is an investigational immunotherapy being evaluated in a Phase 2 clinical trial for this indication. The drug is administered to adult female patients as part of a controlled study.
Durvalumab is a monoclonal antibody, indicated by its -mab suffix. It is designed to work within the immune system to fight cancer. The specific molecular target of Durvalumab is not disclosed in the available information, but as an antibody, it is intended to modulate immune responses against tumor cells.
Durvalumab is being developed by BioAtla, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol BCAB. BioAtla is conducting clinical research to evaluate the safety and efficacy of Durvalumab in patients with ovarian cancer.
Durvalumab is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is recruiting patients to further assess its potential as a treatment for platinum resistant high grade serous ovarian cancer.
Durvalumab is being evaluated in a single Phase 2 clinical trial with the identifier NCT04918186. This study is titled "Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer" and is currently recruiting participants. The trial is being conducted in the United States and Canada, with a planned enrollment of 60 female patients aged 18 years and older.
Durvalumab is a distinct drug candidate developed by BioAtla, Inc. It is not known to be the same as any other marketed medication. As a monoclonal antibody, it is part of a class of immunotherapies, but its specific identity and mechanism are unique to this investigational product.